Anthony Creber is a partner and Head of its IP Litigation Group in the firm's Ottawa office. His practice relates mostly to Patent matters but includes trade-mark litigation, regulatory issues and advising on strategic IP life cycle matters. Anthony's primary focus has been in chemical and pharmaceutical patent litigation. He has appeared extensively in the Federal Court (both Trial and Appeal and including the Supreme Court of Canada) on patent matters, including questions of patentability of life forms, patent licensing and the infringement of biotech patents, including the recent SCC decision in Schmeiser v. Monsanto. Generally Anthony appears for patentees and represents many major pharmaceutical companies, including Eli Lilly, GSK, BMS, Novartis, Hoffmann-La Roche, Janssen-Ortho, and Sanofi. As the lead partner in the Apotex v. Sanofi-Synthelabo Canada case, Anthony won the coveted "Patent Case of the Year 2009" award given by Managing Intellectual Property. The Financial Times (Europe) recently featured Anthony's patent victory for the same case wherein the Canadian Federal Court granted Sanofi’s request to block a challenge by Apotex, Canada’s leading generic drugmaker, against its Plavix patent. He has also upheld Novartis' patent relating to the breakthrough drug Gleevec. He is a Registered Patent and Trade-mark Agent and is permitted to practice before the U.S. Patent and Trade-mark Office as a Patent Agent.